Non-viral gene therapy for myocardial engineering

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 2, Issue 3, 2010, Pages 232-248

  Holladay, Carolyn A ^a   O'Brien, Timothy ^a   Pandit, Abhay ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUPPLY; CARDIAC GENES; CARDIAC TISSUES; CELL-MEDIATED GENE THERAPY; CLINICAL TRIAL; GENE DELIVERY; GENETICALLY MODIFIED; IMMUNOGENICITY; INSERTIONAL MUTAGENESIS; MYOCARDIAL ENGINEERING; MYOCARDIAL INFARCTION; NAKED PLASMID; NONVIRAL GENE THERAPY; PARACRINE; PRE-CLINICAL; SIGNIFICANT IMPACTS; TRANSFECTION EFFICIENCY;

GENE TRANSFER; NUCLEIC ACIDS; STEM CELLS;

GENE THERAPY;

PLASMID DNA;

BIOENGINEERING; EXPRESSION VECTOR; GENE THERAPY; GENE VECTOR; HEART INFARCTION; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION ROUTES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; MYOCARDIAL INFARCTION; PLASMIDS;

EID: 77953669383     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.60     Document Type: Review

References (131)

1. Guyton AC, Hall JE. Unit IV: The Circulation. Textbook of Medical Physiology. Philadelphia: WB Saunders; 2000, 228-240.
2. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008, 8:911-922.
3. Wong SY, Pelet JM, Putnam D. Polymer systems for gene delivery-past, present, and future. Prog Polym Sci 2007, 32:799-837.
4. Davis J, Westfall MV, Townsend D, Blankinship M, Herron TJ, et al. Designing heart performance by gene transfer. Physiol Rev 2008, 88:1567-1651.
5. Segura T, Shea LD.Materials for non-viral gene delivery. Annu Rev Mater Res 2001, 31:25-46.
6. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther 2002, 2:183-194.
7. Boink GJJ, Seppen J, de Bakker JMT, Tan HL. Biological pacing by gene and cell therapy. Netherlands Heart J 2007, 15:318-322. (Pubitemid 350075129)
8. Sylven C. Angiogenic gene therapy. Drugs Today 2002, 38:819-827.
9. Lyon AR, Sato M, Hajjar RJ, Samulski RJ, Harding SE. Gene therapy: targeting the myocardium. Heart 2008, 94:89-99.
10. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Controlled Release 2001, 73:401-416.
11. Uchida E, Mizuguchi H, Ishii-Watabe A, Hayakawa T. Comparison of the efficiency and safety of nonviral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002, 25:891-897.
12. Lundqvist A, Noffz G, Pavlenko M, Saeboe-Larssen S, Fong T, et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2002, 25:445-454.
13. Templeton NS. Liposomal delivery of nucleic acids in vivo. DNA Cell Biol 2002, 21:857-867.
14. Kodama K, Katayama Y, Shoji Y, Nakashima H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 2006, 13:2155-2161.
15. Zhdanov RI, Podobed OV, Vlassov VV. Cationic lipid-DNA complexes - lipoplexes - for gene transfer and therapy. Bioelectrochemistry 2002, 58:53-64.
16. Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci 2008, 97:726-745.
17. Hosseinkhani H. DNA nanoparticles for gene delivery to cells and tissue. Int J Nanotechnol 2006, 3:416-461.
18. Hosseinkhani H, Azzam T, Kobayashi H, Hiraoka Y, Shimokawa H, et al. Combination of 3D tissue engineered scaffold and non-viral gene carrier enhance in vitro DNA expression of mesenchymal stem cells. Biomaterials 2006, 27:4269-4278.
19. Hosseinkhani H, Inatsugu Y, Hiraoka Y, Inoue S, Shimokawa H, et al. Impregnation of plasmid DNA into three-dimensional scaffolds and medium perfusion enhance in vitro DNA expression of mesenchymal stem cells. Tissue Eng 2005, 11:1459-1475.
20. Hosseinkhani H, Yamamoto M, Inatsugu Y, Hiraoka Y, Inoue S, et al. Enhanced ectopic bone formation using a combination of plasmid DNA impregnation into 3-D scaffold and bioreactor perfusion culture. Biomaterials 2006, 27:1387-1398.
21. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Nat Acad Sci USA 1995, 92:7297-7301.
22. Jo JI, Tabata Y. Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J Pharm Biopharm 2008, 68:90-104.
23. Lampela P, Soininen P, Urtti A, Mannisto PT, Raasmaja A. Synergism in gene delivery by small PEIs and three different nonviral vectors. Int J Pharm 2004, 270:175-184.
24. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811. (Pubitemid 28099681)
25. Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. J Controlled Release 2007, 118:357-363.
26. Krajcik R, Jung A, Hirsch A, Neuhuber W, Zolk O. Functionalization of carbon nanotubes enables noncovalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes. Biochem Biophys Res Commun 2008, 369:595-602.
27. Tsunoda S, Mazda O, Oda Y, Iida Y, Akabame S, et al. Sonoporation using microbubble BR14 promotes pDNA/siRNA transduction to murine heart. Biochem Biophys Res Commun 2005, 336:118-127.
28. Doenecke A, Frank E, Scherer MN, Schlitt HJ, Geissler EK. Prolongation of heart allograft survival after longterm expression of soluble MHC class I antigens and vIL-10 in the liver by AAV-plasmid-mediated gene transfer. Langenbecks Arch Surg 2008, 393:343-348.
29. Huang JH, Ito Y, Kobune M, Sasaki K, Nakamura K, et al. Myocardial injection of CA promoter-based plasmid mediates efficient transgene expression in rat heart. J Gen Intern Med 2003, 5:900-908.
30. Jeong JO, Byun J, Jeon ES, Gwon HC, Lim YS, et al. Improved expression by cytomegalovirus promoter/ enhancer and behavior of vascular endothelial growth factor gene aftermyocardial injection of naked DNA. Exp Mol Med 2002, 34:278-284.
31. Gepstein L. Stem cells as biological heart pacemakers. Expert Opin Biol Ther 2005, 5:1531-1537.
32. Gepstein L. Experimental molecular and stem cell therapies in cardiac electrophysiology. In: Sideman SBRLA. ed. Control and Regulation of Transport Phenomena in the Cardiac System 2008, 224-231.
33. Caspi O, Huber I, Kehat I, Habib M, Arbel G, et al. Transplantation of human embryonic stem cell-derived cardiomyocytes improves myocardiol performance in infrcted rat hearts. J Am Coll Cardiol 2007, 50:1884-1893.
34. Yankelson L, Feld Y, Bressler-Stramer T, Itzhaki I, Huber I, et al. Cell therapy for modification of the myocardial electrophysiological substrate. Circulation 2008, 117:720-731.
35. Edelberg JM, Huang DT, Josephson ME, Rosenberg RD. Molecular enhancement of porcine cardiac chronotropy. Heart 2001, 86:559-562.
36. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, et al. In Vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001, 103:1311-1316.
37. Potapova I, Plotnikov A, Lu ZJ, Danilo P, Valiunas V, et al. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res 2004, 94:952-959.
38. Tomiyasu K, Oda Y, Nomura M, Satoh E, Fushiki S, et al. Direct intra-cardiomuscular transfer of beta(2)-adrenergic receptor gene augments cardiac output in cardiomyopathic hamsters. Gene Ther 2000, 7:2087-2093.
39. Edelberg JM, Aird WC, Rosenberg RD. Enhancement of murine cardiac chronotropy by themolecular transfer of the human beta(2) adrenergic receptor cDNA. J Clin Invest 1998, 101:337-343.
40. Kloner RA, Przyklenk K, Whittaker P. Deleterious effects of oxygen radicals in ischemia reperfusionresolved and unresolved issues. Circulation 1989, 80:1115-1127.
41. Ferrari R, Alfieri O, Curello S, Ceconi C, Cargnoni A, et al. Occurrence of oxidative stress during reperfusion of the human heart. Circulation 1990, 81:201-211.
42. Suzuki K, Sawa Y, Kaneda Y, Ichikawa H, Shirakura R, et al. In vivo gene transfection with heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat. J Clin Invest 1997, 99:1645-1650.
43. Jayakumar J, Suzuki K, Khan M, Smolenski RT, Farrell A, et al. Gene therapy formyocardial protection - transfection of donor hearts with heat shock protein 70 gene protects cardiac function against ischemiareperfusion injury. Circulation 2000, 102:302-306.
44. Jayakumar J, Suzuki K, Sammut IA, Smolenski RT, Khan M, et al. Heat shock protein 70 gene transfection protects mitochondrial and ventricular function against ischemia-reperfusion injury. Circulation 2001, 104:I303-I307.
45. Tang YL, Tang Y, Zhang YC, Qian KP, Shen LP, et al. Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system. Hypertension 2004, 43:746-751.
46. Tang YL, Qian KP, Zhang YC, Shen LP, Phillips MI. A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart limits cardiac injury after ischemia-reperfusion in vivo. J Cardiovasc Pharmacol Ther 2005, 10:251-263.
47. Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, et al. A novel strategy for myocardial protection using in vivo transfection of cis element 'decoy' against NFkB binding site - evidence for a role of NFkB in ischemia-reperfusion injury. Circulation 1997, 96:280-284.
48. Palffy R, Gardlik R, Hodosy J, Halcak L, Celec P. Antioxidative gene therapy using superoxide dismutase in ischemia-reperfusion injury of testes in rats. Gene Ther Mol Biol 2006, 10A:55-59.
49. Kutschka I, Kofidis T, Chen IY, von Degenfeld G, Zwierzchoniewska M, et al. Adenoviral human BCL-2 transgene expression attenuates early donor cell death after cardiomyoblast transplantation into ischemic rat hearts. Circulation 2006, 114:1-174-1-180.
50. Session of the American-Heart-Association. Dallas, 2005, I174-I180.
51. Jo JI, Nagaya N, Miyahara Y, Kataoka M, Harada-Shiba M, et al. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, cationized dextran. Tissue Eng 2007, 13:313-322.
52. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003, 108:889-895.
53. De Muinck ED, Nagy N, Tirziu D, Murakami M, Gurusamy N, et al. Protection against myocardial ischemia-reperfusion injury by the angiogenic master-switch protein PR 39 gene therapy: the roles of HIF1 alpha stabilization and FGFR1 signaling. Antioxid Redox Signal 2007, 9:437-445.
54. Jugdutt BI. Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly. Heart Fail Rev 2008, 13:439-452.
55. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008, 130:147-158.
56. Lim BK, Choe SC, Shin JO, Ho SH, Kim JM, et al. Local expression of interleukin-1 receptor antagonist by plasmid DNA improves mortality and decreases myocardial inflammation in experimental coxsackieviral myocarditis. Circulation 2002, 105:1278-1281.
57. Liu H, Hanawa H, Yoshida T, Elnaggar R, Hayashi M, et al. Effect of hydrodynamics-based gene delivery of plasmid DNA encoding interleukin-1 receptor antagonist-Ig for treatment of rat autoimmune myocarditis - Possible mechanism for lymphocytes and noncardiac cells. Circulation 2005, 111:1593-1600.
58. Nakano A, Matsumori A, Kawamoto S, Tahara H, Yamato E, et al. Cytokine gene therapy for myocarditis by in vivo electroporation. Hum Gene Ther 2001, 12:1289-1297.
59. Sugano M, Hata T, Tsuchida K, Suematsu N, Oyama J, et al. Local delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following ischemia/reperfusion injury in rats. Mol Cell Biochem 2004, 266:127-132.
60. Sugano M, Tsuchida K, Hata T, Makino N. In vivo transfer of soluble TNF-alpha receptor 1 gene improves cardiac function and reduces infarct size after myocardial infarction in rats. FASEB J 2004, 18:911.
61. Choi J-J, Yoo SA, Park SJ, Kang YJ, Kim WU, et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol 2008, 153:269-276.
62. Zhang N, Cui HD, Xue HX. Effect of local viral transfer of interleukin 10 gene on a rabbit arthritis model induced by interleukin 1 beta. Chin Med J 2008, 121:435-438.
63. Martins S, de Perrot M, Imai Y, Yamane M, Quadri SM, et al. Transbronchial administration of adenoviral-mediated interleukin-10 gene to the donor improves function in a pig lung transplant model. Gene Ther 2004, 11:1786-1796.
64. Okada Y, Zuo XJ, Toyoda M, Marchevsky A, Matloff JM, et al. Adenovirus mediated IL-10 gene transfer to the airway of the rat lung for prevention of lung allograft rejection. Transpl Immunol 2006, 16:95-98.
65. Kim YH, Lim DG, Wee YM, Kim JH, Yun CO, et al. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant 2008, 17:609-618.
66. Hong YS, Laks H, Cui GG, Chong T, Sen LY. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002, 21:1188-1200.
67. Oshima K, Cui GG, Tung T, Okotie O, Laks H, et al. Exogenous IL-10 overexpression reduces perforin production by activated allogenic CD8+ cells and prolongs cardiac allograft survival. Am J Physiol Heart Circ Physiol 2007, 292:H277-H284.
68. Oshima K, Sen L, Cui GG, Tung T, Sacks BM, et al. Localized interleukin-10 gene transfer induces apoptosis of alloreactive T cells via Fas/FasL pathway, improves function, and prolongs survival of cardiac allograft. Transplantation 2002, 73:1019-1026.
69. Elnaggar R, Hanawa H, Liu H, Yoshida T, Hayashi M, et al. The effect of hydrodynamics-based delivery of an IL-13-Ig fusion gene for experimental autoimmune myocarditis in rats and its possible mechanism. Eur J Immunol 2005, 35:1995-2005.
70. Chang H, Hanawa H, Liu H, Yoshida T, Hayashi M, et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol 2006, 177:3635-3643.
71. Mizuno T, Mickle DAG, Kiani CG, Li RK. Overexpression of elastin fragments in infarcted myocardium attenuates scar expansion and heart dysfunction. Am J Physiol Heart Circ Physiol 2005, 288:H2819-H2827.
72. Mizuno T, Yau TM, Weisel RD, Kiani CG, Li RK. Elastin stabilizes an infarct and preserves ventricular function. Circulation 2005, 112:I81-I88.
73. Takekubo M, Tsuchida M, Haga M, Saitoh M, Hanawa H, et al. Hydrodynamics-based delivery of plasmid DNA encoding CTLA4-1g prolonged cardiac allograft survival in rats. J Gen Intern Med 2008, 10:290-297.
74. Abe S, Hanawa M, Hayashi M, Yoshida M, Komura S, et al. Prevention of experimental autoimmune myocarditis by hydrodynamics-based naked plasmid DNA encoding CTLA4-Ig gene delivery. J Card Fail 2005, 11:557-564.
75. Matsuno Y, Iwata H, Umeda Y, Takagi H, Mori Y, et al. Nonviral gene gun mediated transfer into the beating heart. ASAIO J 2003, 49:641-644.
76. Kawauchi M, Suzuki J, Morishita R, Wada Y, Izawa A, et al. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates. Circ Res 2000, 87:1063-1068.
77. Geissler EK, Graeb C, Tange S, Guba M, Jauch KW, et al. Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients. Hum Gene Ther 2000, 11:459-469.
78. Zou YZ, Takano H, Mizukami M, Akazawa H, Qin YJ, et al. Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 2003, 108:748-753.
79. Furukawa H, Oshima K, Tung T, Cui GG, Laks H, et al. Liposome-mediated combinatorial cytokine gene therapy induces localized synergistic immunosuppression and promotes long-term survival of cardiac allografts. J Immunol 2005, 174:6983-6992.
80. Furukawa H, Oshima K, Tung T, Cui GG, Laks H, et al. Overexpressed exogenous IL-4 and IL-10 paradoxically regulate allogenic T-Cell and cardiac myocytes apoptosis through FAS/FASL pathway. Transplantation 2008, 85:437-446.
81. Sen L, Hong YS, Luo HM, Cui GG, Laks H. Efficiency, efficacy, and adverse effects of adenovirus vs. liposome-mediated gene therapy in cardiac allografts. Am J Physiol Heart Circ Physiol 2001, 281:H1433-H1441.
82. Palaniyandi SS, Watanabe K, Ma ML, Tachikawa H, Kodama M, et al. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur J Immunol 2004, 34:3508-3515.
83. Chang H, Hanawa H, Yoshida T, Hayashi M, Liu H, et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer. Circ J 2008, 72:813-819.
84. Gengrinovitch S, Greenberg SM, Cohen T, Gitay-Goren H, Rockwell P, et al. Platelet factor-4 inhibits the mitogenic activity of VEGF[IMAGE] and VEGF[IMAGE] using several concurrent mechanisms. J Biol Chem 1995, 270:15059-15065.
85. Dai J, Rabie ABM. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 2007, 86:937-950.
86. Vale PR, Losordo DW, Milliken CE, McDonald MC, Gravelin LM, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001, 103:2138-2143.
87. Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004, 109:1029-1035.
88. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003, 92:1098-1106.
89. Jacobs J. Combating cardiovascular disease with angiogenic therapy. Drug Discov Today 2007, 12:1040-1045.
90. Rong SI, Lu YX, Liao YH, Wang XL, Wang YJ, et al. Effects of transplanted myoblasts transfected with human growth hormone gene on improvement of ventricular function of rats. Chin Med J 2008, 121:347-354.
91. Chen XH, Minatoguchi S, Kosai K, Yuge K, Takahashi T, et al. In vivo hepatocyte growth factor gene transfer reduces myocardial ischemia-reperfusion injury through its multiple actions. J Card Fail 2007, 13:874-883.
92. Azuma J, Taniyama Y, Takeya Y, Iekushi K, Aoki M, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cardiomyopathy. Gene Ther 2006, 13:1206-1213.
93. Li XS, Wang ZG, Ran HT, Li XL, Yuan QY, et al. Experimental research on therapeutic angiogenesis induced by hepatocyte growth factor directed by ultrasound-targeted microbubble destruction in rats. J Matern Fetal Investig 2008, 27:453-460.
94. Guo YH, He JG, Wu JL, Yang L, Dai SM, et al. Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res 2008, 39:179-188.
95. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Chatterjee S, et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation 2003, 108:230-236.
96. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, et al. 17th Annual Meeting of the Society-for-Vascular-Medicine-and-Biology, Philadelphia, PA; 2006, 58-65.
97. Serose A, Prudhon B, Salmon A, Doyennette MA, Fiszman MY, et al. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Res Cardiol 2005, 100:161-170.
98. Liu TB, Fedak PWM, Weisel RD, Yasuda T, Kiani G, et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol 2004, 287:H2840-H2849.
99. Li W, Tanaka K, Morioka K, Takamori A, Handa M, et al. Long-term effect of gene therapy for chronic ischemic myocardium using platelet-derived endothelial cell growth factor in dogs. J Gen Intern Med 2008, 10:412-420.
100. Tang YL, Qian KP, Zhang YC, Shen LP, Phillips MI. Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1 alpha (SDF-1 alpha) treatment. Regul Pept 2005, 125:1-8.
101. Liu X, Chen Y, Zhang F, Chen L, Ha T, et al. Synergistically therapeutic effects of VEGF165 and angiopoietin-1 on ischemic rat myocardium. Scand Cardiovasc J 2007, 41:95-101.
102. Iwata A, Sai S, Nitta Y, Chen M, de Fries-Hallstrand R, et al. Liposome-mediated gene transfection of endothelial nitric oxide synthase reduces endothelial activation and leukocyte infiltration in transplanted hearts. Circulation 2001, 103:2753-2759.
103. Christman KL, Fang QZ, Yee MS, Johnson KR, Sievers RE, et al. Enhanced neovasculature formation in ischemic myocardium following delivery of pleiotrophin plasmid in a biopolymer. Biomaterials 2005, 26:1139-1144.
104. Ye L, Haider HK, Jiang S, Tan RS, Ge RW, et al. Improved angiogenic response in pig heart following ischaemic injury using human skeletal myoblast simultaneously expressing VEGF(165) and angiopoietin-1. Eur J Heart Fail 2007, 9:15-22.
105. Suzuki K, Murtuza B, Smolenski RT, Sammut IA, Suzuki N, et al. Cell transplantation for the treatment of acutemyocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001, 104:I207-I212.
106. Miyagawa S, Sawa Y, Fukuda K, Hisaka Y, Taketani S, et al. Angiogenic gene cell therapy using suicide gene system regulates the effect of angiogenesis in infarcted rat heart. Transplantation 2006, 81:902-907.
107. Yang JF, Zhou WW, Zheng W, Ma YL, Lin L, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 2007, 107:17-29.
108. Pelisek J, Fuchs A, Engelmann MG, Shimizu M, Golda A, et al. Vascular endothelial growth factor response in porcine coronary and peripheral arteries using nonsurgical occlusion model, local delivery, and liposome-mediated gene transfer. Endothelium 2003, 10:247-255.
109. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia - Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683.
110. Wang ZG, Ling ZY, Ran HT, Hong R, Zhang QX, et al. Ultrasound-mediated microbubble destruction enhances VEGF gene delivery to the infarcted myocardium in rats. Clin Imaging 2004, 28:395-398.
111. Saeed M, Martin A, Ursell P, Do L, Bucknor M, et al. MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology 2008, 249:107-118.
112. Shirakawa Y, Sawa Y, Takewa Y, Tatsumi E, Kaneda Y, et al. Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices. J Thorac Cardiovasc Surg 2005, 130:624-632.
113. Ojalvo AG, Seralena A, Vispo NS, Silva R, Gonzalez N, et al. Intramyocardial gene transfer of vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. Elec J Biotechnol 2004, 7:267-276.
114. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, et al. Intramyocardial injection of vascular endothelial growth factor-A(165) plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006, 27:1785-1792.
115. Son MK, Choi DH, Lee DS, Kim CY, Choi SM, et al. Pharmacokinetics and biodistribution of a pGT(2)-VEGF plasmid DNA after administration in rats. J Cardiovasc Pharmacol 2005, 46:577-584.
116. Gyongyosi M, Khorsand A, Zamini S, Sperker W, Strehblow C, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia - subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005, 112:I157-I165.
117. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy - restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005, 111:2073-2085.
118. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A(165)-gene therapy in patients with stable severe angina pectoris - a randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005, 45:982-988.
119. Radke PW, Heinl-Green A, Frass OM, Griesenbach U, Ferrari S, et al. Effects of intramyocardial pVEGF(165) delivery on regional myocardial blood flow: evidence for a spatial 'delivery-efficacy' mismatch. Gene Ther 2004, 11:1249-1255.
120. Sarkar N, Blomberg P, Wardell E, Eskandarpour M, Sylven C, et al. Nonsurgical direct delivery of plasmid DNA into rat heart: time course, dose response, and the influence of different promoters on gene expression. J Cardiovasc Pharmacol 2002, 39:215-224.
121. Kloner RA, Dow J, Chung G, Kedes LH. Intramyocardial injection of DNA encoding vascular endothelial growth factor in a myocardial infarction model. J Thromb Thrombolysis 2000, 10:285-289.
122. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J Am Coll Cardiol 2000, 35:1323-1330.
123. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, et al. Gene therapy for myocardial angiogenesis - initial clinical results with direct myocardial injection of phVEGF(165) as sole therapy for myocardial ischemia. Circulation 1998, 98:2800-2804.
124. Wang YZ, Ripa RS, Jorgensen E, Hesse B, Mortensen S, et al. Mobilization of haematopoietic and nonhaematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease. Scand Cardiovasc J 2007, 41:397-404.
125. Quarck R, Holvoet P. Gene therapy approaches for cardiovascular diseases. Curr Gene Ther 2004, 4:207-223.
126. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003, 92:436-439.
127. Kaye DM, Hoshijima M, Chien KR. Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med 2008, 59:13-28.
128. Lee M, Park H, Youn J, Oh ET, Ko K, Kim SW, Park Y. Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes. In Sanjeevi CB and Hanafusa T, eds. Immunology of Diabetes IV: Progress in our understanding. Oxford: Blackwell, 2006, pp 313-319.
129. Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, et al. Effects of intramyocardial injection of phVEGF-A (165) as sole therapy in patients with refractory coronary artery disease - 12-month followup: angiogenic gene therapy. J Intern Med 2001, 250:373-381.
130. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105:2012-2018.
131. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 2000, 97:793-798.